Source: International Congress 2014 – Novel evidence relating to respiratory treatment development



Rating:

Share or cite this content

Citations should be made in the following way:
R. Sandhaus, K. R. Chapman, J. Burdon, E. Piitulainen, N. Seersholm, J. Stocks, J. Edelman, M. Bexon, L. Huang, N. G. McElvaney (Denver, Tyler, King of Prussia, United States Of America; Toronto, Canada; Melbourne, Australia; Malmo, Sweden; Hellerup, Denmark; Bern, Switzerland; Dublin, Ireland). Integrated safety across six clinical trials of alpha-1 augmentation therapy. Eur Respir J 2014; 44: Suppl. 58, 950

Member's Comments

No comment yet.

Related content which might interest you: Long-term efficacy of A1-PI therapy in RAPID and its extension study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Treatment with low-dose everolimus in patients with sporadic lymphangioleiomyomatosis (LAM) Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 The Severe Paediatric Asthma Collaborative in Europe (SPACE) ERS Clinical Research Collaboration: enhancing participation of children with asthma in therapeutic trials of new biologics and receptor blockers Source: Eur Respir J, 52 (4) 1801665; 10.1183/13993003.01665-2018 Year: 2018 Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Efficacy and safety of abediterol, a long-acting beta2-adrenergic agonist (LABA); three phase II trials in asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Safety and tolerability of acute dosing of beta-blockers in asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Translational study searching for synergy between glycopyrronium and indacaterol Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Efficacy of omalizumab in Polish real-world patients Source: International Congress 2016 – Asthma management Year: 2016 Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS) Source: International Congress 2014 – Asthma and COPD management Year: 2014 Safety of tiotropium in renally impaired patients Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effectively targeting small airways using controlled inhalation for peripheral corticosteroid deposition Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Management of selexipag interruptions in the GRIPHON study Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Dissociation between clinical trial inclusion and exclusion criteria for trials in severe asthma and the reality of the patient population Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Inflammation in COPD patients before and after roflumilast treatment Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014